Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Ischemic stroke" wg kryterium: Temat


Wyświetlanie 1-3 z 3
Tytuł:
Uncomplicated dissection of the right internal carotid artery with coexisting left-sided ischemic stroke - case report
Autorzy:
Poleszak, Julita
Morawska, Izabela
Gierszon, Patrycja
Szpiech, Kamil
Wiśniewski, Karol
Milanowska, Joanna
Furgał, Michał
Powiązania:
https://bibliotekanauki.pl/articles/1163566.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
carotid dissection
ischemic stroke
Opis:
The dissection of the internal carotid artery, although rare, is in five to twenty-five percent a causative agent of acute ischemic stroke in patients up to the age of 45. The aim of this paper is to present the case of ischemic stroke within the right hemisphere with left-sided uncomplicated dissection of the internal carotid artery in the case of a young woman. A 35-year-old patient was admitted to the Department of Neurology on an emergency basis due to the sudden motor dysphasia and paresis of the right upper limb. During the anamnesis, the woman reported a head injury suffered two days earlier as a result of fainting. Diagnostic procedures toward ischemic stroke indicated a presence of hypodense area within the left hemisphere of the brain. Subsequent studies – MRI, CT angiography confirmed the existence of an ischemic lesion in the area of the left middle cerebral artery as a consequence of obstruction of the left internal carotid artery. In addition, a dissection of the right internal carotid artery was revealed. Further differential diagnosis, including systemic diseases, did not reveal the reasons for the coexistence of ischemic stroke and vessel dissection on the opposite side. Carotid dissection is a rare but dangerous condition. It either develops spontaneously or after an injury to the head or neck. Any kind of injury of the carotid artery can cause dissection and should lead to include this condition in the differential diagnosis- the more so since even small dissection of the internal carotid artery can be manifested with a delay.
Źródło:
World Scientific News; 2018, 109; 235-244
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The comparison of tenecteplase and alteplase in acute stroke treatment: meta-analysis of 5 randomized clinical trials
Autorzy:
Marciniec, Michał
Szczepańska-Szerej, Anna
Kulczyński, Marcin
Popek-Marciniec, Sylwia
Wyjadłowska, Karolina
Rejdak, Konrad
Powiązania:
https://bibliotekanauki.pl/articles/1177755.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
alteplase
cerebral infarction
ischemic stroke
rt-PA
tenecteplase
thrombolysis
Opis:
Thrombolysis with the use of intravenously administrated alteplase is the only approved thrombolytic treatment of acute ischemic stroke. Tenecteplase is a fibrinolytic protein bioengineered from human tissue plasminogen activator with higher fibrin specificity, enhanced affinity to fibrin-rich clots, faster clot lysis and prolonged plasma half-life. The aim of this study was to determine which thrombolytic therapy (tenecteplase versus alteplase) provides better efficacy and safety outcomes. Eligible studies for meta-analysis published from their inception to May 2018 were identified through a search of PubMed database and two clinical trial registries websites: ClinicalTrials.gov and EU Clinical Trials Register. A meta-analysis was conducted with the use of Statistica software version 13.1. Five studies comprising 1529 patients were included. Tenecteplase 0,25mg/kg administration resulted in significantly higher number of patients with excellent score (0-1) in modified Rankin Scale at 90 days compared to alteplase group (RR 1,30, p=0,0215, 95% CI 1,04–1,62). Additionally, more patients treated with tenecteplase 0,25 mg/kg tended to develop favorable score changes in NIHSS at 24 hours after stroke onset (>8 point improvement, scale quantifying stroke severity) compared to alteplase treatment (RR 1,60, p=0,0545, 95% CI 0,99–2,58). No above correlation were observed in higher dose of tenecteplase group (0,4 mg/kg). There were no significant differences in the frequency of symptomatic intracerebral hemorrhage (ICH) and the mortality rates within 90 days after stroke onset in comparison of tenecteplase and alteplase groups. Tenecteplase 0,25 mg/kg administration in acute ischemic stroke resulted in better functional outcome at 90 days after ischemic stroke onset and tended to restrict the severity of stroke at 24 hours in NIHSS compared to alteplase 0,9 mg/kg. The frequency of symptomatic ICH occurrence and mortality within 3 months between tenecteplase and alteplase were comparable.
Źródło:
World Scientific News; 2018, 100; 61-73
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Prevention of seizures after ischemic stroke: association between statin use and the risk of seizures
Autorzy:
Marciniec, Michał
Popek-Marciniec, Sylwia
Kulczyński, Marcin
Pasterczyk, Katarzyna
Szczepańska-Szerej, Anna
Rejdak, Konrad
Powiązania:
https://bibliotekanauki.pl/articles/1177817.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
HMG-CoA reductase inhibitor
Post-stroke seizure
epilepsy
ischemic stroke
rt-PA
statin
Opis:
More than 50 million people worldwide suffer from epilepsy. In approximately 50% cases of newly diagnosed patients over 60 years of age seizures are related to stroke. Post-stroke lesions in brain tissue may result in 7 fold increase risk of seizures compared to the general population. The most significant risk factors for post-stroke seizures (PSS) and post-stroke epilepsy (PSE) include stroke severity, intracerebral or subarachnoid hemorrhage and cortical involvement. Increased incidence of PSS was also observed in younger patients especially with previous early PSS occurrence. Statins (HMG-CoA reductase inhibitors) are a class of lipid-lowering medications characterized by neuroprotective and antiepileptic effects. The main result of the performed studies was significantly reduced risk of developing PSS associated with a post-stroke, but not pre-stroke statin use. Moderate to high doses of statin and early administration in acute phase of stroke potentiated the beneficial effects of the treatment. The evidences for the association between PSS prevention and statin treatment become more significant, however the most recent AHA/ASA recommendations do not include any medications in the PSS prophylaxis. This article summarizes the current knowledge about the prediction and prevention of PSS and PSE.
Źródło:
World Scientific News; 2018, 99; 181-192
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies